- Home
- ATCH vs QLGN Comparison
ATCH vs QLGN Comparison
Compare ATCH & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATCH
- QLGN
- Stock Information
- Founded
- ATCH 2022
- QLGN 1996
- Country
- ATCH United States
- QLGN United States
- Employees
- ATCH N/A
- QLGN N/A
- Industry
- ATCH
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- ATCH
- QLGN Health Care
- Exchange
- ATCH Nasdaq
- QLGN Nasdaq
- Market Cap
- ATCH 2.5M
- QLGN 2.4M
- IPO Year
- ATCH N/A
- QLGN N/A
- Fundamental
- Price
- ATCH $2.35
- QLGN $3.55
- Analyst Decision
- ATCH
- QLGN
- Analyst Count
- ATCH 0
- QLGN 0
- Target Price
- ATCH N/A
- QLGN N/A
- AVG Volume (30 Days)
- ATCH 250.1K
- QLGN 110.9K
- Earning Date
- ATCH 02-19-2025
- QLGN 04-07-2025
- Dividend Yield
- ATCH N/A
- QLGN N/A
- EPS Growth
- ATCH N/A
- QLGN N/A
- EPS
- ATCH 2.67
- QLGN N/A
- Revenue
- ATCH N/A
- QLGN N/A
- Revenue This Year
- ATCH N/A
- QLGN N/A
- Revenue Next Year
- ATCH N/A
- QLGN N/A
- P/E Ratio
- ATCH $0.88
- QLGN N/A
- Revenue Growth
- ATCH N/A
- QLGN N/A
- 52 Week Low
- ATCH $1.73
- QLGN $2.96
- 52 Week High
- ATCH $209.40
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- ATCH 23.48
- QLGN 47.06
- Support Level
- ATCH $1.73
- QLGN $3.16
- Resistance Level
- ATCH $2.40
- QLGN $3.75
- Average True Range (ATR)
- ATCH 0.60
- QLGN 0.21
- MACD
- ATCH 0.07
- QLGN 0.06
- Stochastic Oscillator
- ATCH 20.53
- QLGN 67.25
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.